Brand Reference: Provigil
| Metric | Verified Benchmark | Source |
|---|---|---|
| Modafinil RxNorm Concept ID | 30125 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.3200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $248.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $14.20 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $19.00 / mo | 34 Zero-PHI Verified Patient Logs |
Atypical non-amphetamine benzhydrylsulfinyl wakefulness agent that weakly occupies striatal DAT while elevating prefrontal histamine, glutamate, and lateral hypothalamic orexin firing—eliminating obstructive-sleep-apnea residual sleepiness and shift-work circadian collapse without sympathomimetic rebound crash.
Classified under Low-Affinity Dopamine Transporter (DAT) & Hypothalamic Orexin Wakefulness Promoter (Rx), Modafinil exhibits a $233.80/month gap between standard U.S. retail cash counters ($248.00) and verified direct-to-patient routing ($14.20) anchored to $0.3200 CMS unit cost.
Pharmacokinetic profiling of Modafinil demonstrates an elimination half-life of 12–15 hours (R-enantiomer ~15h / S-enantiomer ~4h) with > 80% oral systemic bioavailability; clearance proceeds via 90% hepatic amide hydrolysis and cyp3a4 oxidation (induces cyp3a4—reduces hormonal contraceptive steroidal levels!), reaching clinical onset within 60–90 minutes fasting qam.
Titration schedules for Modafinil (100 mg PO early QAM → 200 mg PO early QAM) require excluding left ventricular hypertrophy or mitral valve prolapse syndrome on stimulants; stevens-johnson rash history; relying solely on steroidal contraceptives without barrier backup; real-world patient logs highlight tension headache (hydrate + choline) (24% of reports), insomnia if taken after 9 am (19% of reports), reduced appetite (14% of reports) alongside a 89.50% Worth-It consensus.
Across 34 verified cash-pay logs, Modafinil achieves a 89.50% Worth-It rating with out-of-pocket spend averaging $19.00/mo versus $248.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 100 mg PO early QAM for Modafinil; monthly out-of-pocket dropped to $12.50 compared with $248.00 retail.
Completed 10 weeks on Modafinil (200 mg PO early QAM). Zero notable side effects on steady dosing.
Consistent biomarker response on 100 mg PO early QAM Modafinil sourced via Local Pharmacy ($16.47/mo cash pay without insurance prior authorization).